Fig. 3.

In vivo activity of afatinib in FaDu cell line-derived xenografts. Mice were treated daily with either vehicle (black circle) or afatinib as described in (white triangle) or in a weekly alternating schedule (white square). Tumor volumes and body weights were recorded three times a week, and median tumor volumes (a) as well as change in body weight (b) were plotted over time